Overview (why partner?)
A number of premier pharmaceutical companies and niche specialist biotech companies already choose to partner with Vernalis. Our partnerships cover both individual drug development programmes, and broader research collaborations. What makes Vernalis such a well-regarded partner?
Why partner with Vernalis?
There are many good reasons.
Companies that enter into partnerships with Vernalis do so primarily because we share a belief that the research or development programme has significant clinical and commercial potential. But a number of other key factors also come into play.
Many partners value our proven clinical expertise. We have well-developed clinical skills, having guided a number of programmes through pre-clinical and early clinical phases. We also took our marketed product, frovatriptan, for the treatment of acute migraine, through Phase III development and into commercialisation partnerships.
We also possess outstanding research and drug discovery capabilities. We have demonstrated that expertise through successes in structure- and fragment-based drug discovery, an increasingly important component of many companies’ drug discovery strategies.
We have highly experienced senior management in place. The Directors and Executive management have successfully grown a number of drug development companies, and are determined to see Vernalis realise its potential.
Finally, we also offer demonstrable financial security. Sales from Tuzistra® XR and Moxatag®, royalties from our marketed product, milestone income and headcount funding from partnership programmes, and successful fundraisings have secured sufficient cash to reach self sustainability.